SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Celldex Therapeutics, Inc. (CLDX) News

Track canonical SquawkNews coverage tagged to CLDX, Celldex Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol CLDX Asset equity Sector Markets 90 days 6 Last 39.1 Updated Sep 08, 2026, 08:01 PM UTC Open live news feed
L CLDX to present at upcoming investor conference CLDX plans to present at an upcoming investor conference. EQUITY | Sep 08, 2026, 08:01 PM UTC L CLDX Celldex Therapeutics shares down 2.6% after scrapping development of skin disease drug CLDX Celldex Therapeutics shares down 2.6% after scrapping development of skin disease drug EQUITY | Jul 22, 2026, 01:34 PM UTC L CLDX Barzolvolimab Misses on PN; CSU Data Expected in September/October Remain the Big Focus @ Cantor CLDX Barzolvolimab Misses on PN; CSU Data Expected in September/October Remain the Big Focus @ Cantor EQUITY | Jul 22, 2026, 01:09 PM UTC L CLDX shares -5.3% premarket after saying its experimental drug barzolvolimab failed in a Phase 2 study in the skin condition prurigo nodular CLDX shares -5.3% premarket after saying its experimental drug barzolvolimab failed in a Phase 2 study in the skin condition prurigo nodularis; is continuing to test the drug in a number of other indications, with data e EQUITY | Jul 22, 2026, 12:35 PM UTC L CLDX Raise PT to $100 from $90 ahead of pivotal EMBARQ-CSU1/2 topline readout (n=1,939) expected in Q426 (GUGG estimate October) @ GUGG CLDX Raise PT to $100 from $90 ahead of pivotal EMBARQ-CSU1/2 topline readout (n=1,939) expected in Q426 (GUGG estimate October) @ GUGG EQUITY | Jul 20, 2026, 01:14 PM UTC L CLDX Celldex announces planned transition of Chief Financial Officer Celldex Therapeutics - celldx CFO sam Martin plans to retire in 2027 CLDX Celldex announces planned transition of Chief Financial Officer Celldex Therapeutics - celldx CFO sam Martin plans to retire in 2027 - Celldx begins search for new CFO; sam Martin to remain through March 2027 EQUITY | Jul 15, 2026, 08:01 PM UTC